Senti Biosciences (SNTI) said Wednesday that the US Food and Drug Administration has granted orphan drug designation for SENTI-202, a drug candidate for relapsed or refractory acute myeloid leukemia.
The experimental drug is a first, off-the-shelf cancer immunotherapy natural killer cell treatment designed to target acute myeloid leukemia and other hematologic malignancies, the company said.
Senti-202 is currently being evaluated in a phase 1 clinical trial to assess its safety and efficacy, Senti Biosciences said.
The orphan drug designation provides benefits such as tax credits, exemptions from certain FDA fees, and potential market exclusivity for seven years, the company added.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。